ReviewEndocrine pathology2021
Genomics and Epigenomics in Parathyroid Neoplasia: from Bench to Surgical Pathology Practice.
Review in Endocrine pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- The role of ESRRA and JUNB in oxyphil cells: insights from spatial transcriptomics and single-cell transcriptomics in uremic secondary hyperparathyroidism.Biology direct · 2026Article
- Genome near-haploidization in CDC73-wildtype parathyroid tumors.Scientific reports · 2026Article
- Parathyroid Carcinoma: From Molecular Pathogenesis and Diagnostic Biomarkers to Targeted Therapeutics.International journal of molecular sciences · 2026Review
- Avoiding overdiagnosis of parathyroid carcinoma.Virchows Archiv : an international journal of pathology · 2026Review
- Atypical Parathyroid Tumor Causing Primary Hyperparathyroidism With a Clinical Presentation of a Brown Tumor.JCEM case reports · 2025Article
- Hyperparathyroidism-Jaw Tumor Syndrome: A Case Diagnosed After the Removal of Multiple Ossifying Fibromas of the Jaws.JCEM case reports · 2025Article
- PET/CT imaging of bone disorders in dysparathyroidism: a comprehensive review.Frontiers in nuclear medicine · 2025Review
- Unusual presentation and management of parathyroid carcinoma with pulmonary metastasis: a case report.AME case reports · 2025Article
- The road ahead: a brief guide to navigating the 2022 WHO classification of endocrine and neuroendocrine tumours.Journal of clinical pathology · 2024Review
- KMT2A and chronic inflammation as potential drivers of sporadic parathyroid adenoma.Clinical and translational medicine · 2024Article
- Syndromic MEN1 parathyroid adenomas consist of both subclonal nodules and clonally independent tumors.Virchows Archiv : an international journal of pathology · 2024Article
- Protein Signatures of Parathyroid Adenoma according to Tumor Volume and Functionality.Endocrinology and metabolism (Seoul, Korea) · 2024Article
- Not All Parafibromin Deficiency Relates to Parathyroid Carcinoma: The Role of Morphological Assessment.Endocrine pathology · 2024Article
- Primary Multiglandular Parathyroid Disease in the Setting of Pompe Disease.Endocrine pathology · 2024Article
- New Perspective on the Genetic Dissection Underlying the Development of Parathyroid Cancer.The Journal of clinical endocrinology and metabolism · 2023Article
- [Special features of the diagnostics and treatment of hereditary primary hyperparathyroidism].Chirurgie (Heidelberg, Germany) · 2023Review
- NovelCancers · 2023Article
- Article
- Preoperative inflammatory markers for predicting parathyroid carcinoma.Endocrine connections · 2022Article
- Metabolic Bone Diseases and New Drug Developments.Biomolecules & therapeutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The majority of parathyroid disease encountered in routine practice is due to single parathyroid adenoma, of which the majority arise as sporadic tumors. This is usually a straightforward diagnosis in endocrine pathology when in the appropriate clinical setting, although subsets of cases will exhibit atypical histological features that may warrant additional immunohistochemical and genetic analyses to estimate the malignant potential. Parathyroid carcinomas on the other hand, are bona fide malignant tumors characterized by their unequivocal invasion demonstrated through routine histology or metastasis. The ultimate endpoint for any molecular marker discovered through laboratory investigations is to be introduced in clinical routine practice and guide the surgical pathologist in terms of diagnostics and prognostication. For parathyroid tumors, the two main diagnostic challenges include the distinction between parathyroid adenoma and parathyroid carcinoma, as well as the pinpointing of hereditable disease for familial screening purposes. While numerous markers on genetic, epigenetic, and protein levels have been proposed as discriminative in these aspects, this review aims to condense the scientific coverage of these enigmatic topics and to propose a focused surgical pathology approach to the subject.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.